TABLE 2.
Ongoing clinical trials of PD‐1 inhibitors or anti‐PD‐1 monoclonal antibodies for NPC
| Experimental regimen | Control regimen | Sample size | Clinical setting | Phase | NCT number | Estimated completion date |
|---|---|---|---|---|---|---|
| Camrelizumab+Gemcitabine+Cisplatin | Placebos+Gemcitabine+Cisplatin | 250 | Recurrent/metastatic NPC | III | NCT03707509 | August 2021 |
| Camrelizumab | Observation | 400 | Stage III‐IVA NPC | III | NCT03427827 | February 2022 |
| Pembrolizumab | Capecitabine/gemcitabine/docetaxel | 233 | Recurrent/metastatic NPC | III | NCT02611960 | November 2020 |
| Sintilimab+Gemcitabine+Cisplatin+IMRT | Gemcitabine+Cisplatin+IMRT | 420 | Stage III‐IVA NPC | III | NCT03700476 | January 2023 |
| Tislelizumab+Gemcitabine+Cisplatin | Placebo+Gemcitabine+Cisplatin | 256 | Recurrent/metastatic NPC | III | NCT03924986 | August 2021 |
| Toripalimab+gemcitabine+cisplatin | Placebo+gemcitabine+cisplatin | 280 | Recurrent/metastatic NPC | III | NCT03581786 | August 2020 |
| AK105 | 153 | Stage IVb NPC | II | NCT03866967 | June 2020 | |
| PDR001 | Chemotherapy | 122 | Recurrent/metastatic NPC | II | NCT02605967 | August 2020 |